RT - Journal TY - JOUR A1 - Khattab, Ahmed A1 - Saleh, Nagwan A1 - Rizk, Mohamed A1 - El-Taweel, Shimaa T1 - Galectin-3 in children with heart failure secondary to congenital heart diseases YR - 2019/10/1 JF - Menoufia Medical Journal JO - Menoufia Med J SP - 1501 OP - 1505 VO - 32 IS - 4 UL - http://www.mmj.eg.net/article.asp?issn=1110-2098;year=2019;volume=32;issue=4;spage=1501;epage=1505;aulast=Khattab;t=5 DO - 10.4103/mmj.mmj_418_18 N2 - Objective The aim was to assess serum level of galectin-3 in children with heart failure (HF) secondary to congenital heart disease (CHD) and correlate it with diagnosis and outcome. Background Galectin-3 is an emerging biomarker that has been linked to tissue fibrosis, a hallmark in cardiac remodeling and HF. Galectin-3 can reliably be measured in the circulation to detect early failure. Patients and methods This prospective cohort study was conducted at Pediatric Intensive Care Units of Menoufia University Hospital from September 2017 to July 2018. The assessed serum galectin-3 levels in 30 children with CHD with HF were compared with 30 children who had CHD without symptoms of HF and 20 apparently healthy children, used as controls, who visited the pediatric outpatient clinic and were subjected to routine clinical examinations. Results The demographic data of the studied groups showed that there was no statistically significant difference among the studied groups regarding sex, age, weight, and height, but there was a statistically significant difference among the studied groups regarding BMI, where P value was 0.03. There was a highly statistically significant difference among the studied groups regarding galectin-3 levels. There was a highly statistically significant correlation between galectin-3 levels and echo finding, i.e., ejection fraction, but there was no statistically significant correlation between galectin-3 and outcome of CHD with or without HF. Conclusion Galectin-3 has a promising diagnostic value in pediatric HF. ER -